APA (7th ed.) Citation

Bridgewater, J., Hollebecque, A., Furuse, J., Goyal, L., Meric-Bernstam, F., Epstein, R., . . . Valle, J. (2022). POSA354 Patient-Reported Outcomes in Futibatinib-Treated Intrahepatic Cholangiocarcinoma Patients with FGFR2 Fusions/Rearrangements: Results from the Foenix-CCA2 Study. Value in Health, 25(1), S218. https://doi.org/10.1016/j.jval.2021.11.1065

Chicago Style (17th ed.) Citation

Bridgewater, JA, et al. "POSA354 Patient-Reported Outcomes in Futibatinib-Treated Intrahepatic Cholangiocarcinoma Patients with FGFR2 Fusions/Rearrangements: Results from the Foenix-CCA2 Study." Value in Health 25, no. 1 (2022): S218. https://doi.org/10.1016/j.jval.2021.11.1065.

MLA (9th ed.) Citation

Bridgewater, JA, et al. "POSA354 Patient-Reported Outcomes in Futibatinib-Treated Intrahepatic Cholangiocarcinoma Patients with FGFR2 Fusions/Rearrangements: Results from the Foenix-CCA2 Study." Value in Health, vol. 25, no. 1, 2022, p. S218, https://doi.org/10.1016/j.jval.2021.11.1065.